Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.
Saved in:
| Title: | Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive. |
|---|---|
| Authors: | Fitz-Patrick, David1 (AUTHOR), Sahgal, Omair2 (AUTHOR), Fouché, Leon F.3 (AUTHOR), Mitha, Essack4 (AUTHOR), Malahleha, Mookho5 (AUTHOR), Gayed, Juleen2 (AUTHOR) juleen.gayed@pfizer.com, Keep, Georgina2 (AUTHOR), Zhang, Ying6 (AUTHOR), Modjarrad, Kayvon6 (AUTHOR), Belanger, Todd6 (AUTHOR), Xu, Xia6 (AUTHOR), Cooper, David6 (AUTHOR), Mensa, Federico J.7 (AUTHOR), Sahin, Uǧur7 (AUTHOR), Türeci, Ӧzlem7 (AUTHOR), Swanson, Kena A.6 (AUTHOR), Anderson, Annaliesa S.6 (AUTHOR), Gurtman, Alejandra6 (AUTHOR), Kitchin, Nicholas2 (AUTHOR) |
| Source: | Infectious Diseases & Therapy. Jul2026, p1-23. 23p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
